Ibrutinib Treatment: Uses, Dosage, Side Effects, and Cost Guide

Summary of Key Points

Ibrutinib is a prescription medication used to treat certain types of cancer, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and others. It works by blocking a protein that helps cancer cells grow, making it an effective treatment option. Ibrutinib is taken orally, typically once a day. While it can be highly effective, it may also cause side effects, so it’s important to follow your doctor’s instructions carefully. For personalized advice on Ibrutinib treatment, consider consulting one of our telemedicine providers.

Names of Medication

US Brand Name: Imbruvica

Generic Name: Ibrutinib

The generic name, Ibrutinib, refers to the active ingredient in the medication and is listed in parentheses after the brand name.

Pharmacologic Category

Ibrutinib belongs to a class of medications known as Bruton’s tyrosine kinase (BTK) inhibitors. Other medications in this category include:

1. Acalabrutinib (Calquence)
2. Zanubrutinib (Brukinsa)

Ibrutinib Dosage

Ibrutinib is used to treat various cancers and conditions, and the dosage may vary depending on the specific diagnosis. Always consult your doctor before making any changes to your Ibrutinib dose.

Ibrutinib for Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Recommended dose: 420 mg orally once daily.

Treatment should continue until the disease progresses or unacceptable side effects occur.

Ibrutinib for Mantle Cell Lymphoma (MCL)

Recommended dose: 560 mg orally once daily.

Treatment should continue until the disease progresses or unacceptable side effects occur.

Ibrutinib for Waldenström’s Macroglobulinemia (WM)

Recommended dose: 420 mg orally once daily.

Treatment should continue until the disease progresses or unacceptable side effects occur.

Ibrutinib for Marginal Zone Lymphoma (MZL)

Recommended dose: 560 mg orally once daily.

Treatment should continue until the disease progresses or unacceptable side effects occur.

Ibrutinib for Chronic Graft-Versus-Host Disease (cGVHD)

Recommended dose: 420 mg orally once daily.

Treatment should continue until the disease progresses or unacceptable side effects occur.

Ibrutinib for Multiple Myeloma (MM)

Recommended dose: 560 mg orally once daily.

Treatment should continue until the disease progresses or unacceptable side effects occur.

Ibrutinib for Follicular Lymphoma (FL)

Recommended dose: 560 mg orally once daily.

Treatment should continue until the disease progresses or unacceptable side effects occur.

Ibrutinib for Diffuse Large B-Cell Lymphoma (DLBCL)

Recommended dose: 560 mg orally once daily.

Treatment should continue until the disease progresses or unacceptable side effects occur.

Dosage Forms and Strengths

Ibrutinib is available in the following forms and strengths:

1. Capsules: 70 mg, 140 mg
2. Tablets: 140 mg, 280 mg, 420 mg, 560 mg

Administration Instructions for Ibrutinib

Ibrutinib should be taken at the same time each day with a full glass of water. It can be taken with or without food. Swallow the tablets or capsules whole; do not crush, chew, or break them. If you miss a dose, take it as soon as you remember, unless it’s close to your next scheduled dose. Do not take two doses at the same time. Always follow your healthcare provider’s instructions, and if you have any questions about your Ibrutinib treatment, consult one of our telemedicine providers.

Ibrutinib Side Effects and Adverse Reactions

Like all medications, Ibrutinib may cause side effects. Some are common and manageable, while others are rare but potentially serious. If you experience any side effects, contact your healthcare provider promptly.

Common Ibrutinib Side Effects

1. Diarrhea: Frequent loose or watery stools.
2. Fatigue: Feeling unusually tired or weak.
3. Nausea: A sensation of sickness in the stomach.
4. Bruising: Increased tendency to bruise easily.

Serious Ibrutinib Side Effects

1. Bleeding: Severe or unusual bleeding, such as nosebleeds or blood in the urine.
2. Infections: Increased risk of infections, which may present as fever, chills, or a sore throat.
3. Heart Problems: Irregular heartbeat or chest pain.
4. High Blood Pressure: Elevated blood pressure that may require monitoring or treatment.

If you experience any of these serious side effects, seek medical attention immediately. You can also consult one of our telemedicine providers for guidance on managing Ibrutinib side effects.

Contraindications for Ibrutinib

A contraindication is a specific condition or situation where a treatment or medication should not be used because it may cause harm. If you have any of the following conditions, Ibrutinib may not be safe for you. Always discuss your medical history with your healthcare provider before starting any new medication, including Ibrutinib.

1. Allergic reaction to Ibrutinib: If you’ve had an allergic reaction to Ibrutinib or any of its ingredients, you should not take this medication. Symptoms of an allergic reaction can include rash, itching, swelling, or difficulty breathing, which can be life-threatening.
2. Active bleeding disorders: Ibrutinib can increase the risk of bleeding. If you have a bleeding disorder, such as hemophilia, or are currently experiencing active bleeding, taking Ibrutinib could worsen your condition.
3. Severe liver disease: Since Ibrutinib is processed by the liver, individuals with severe liver disease may not be able to metabolize the medication properly, leading to increased side effects or toxicity.
4. Recent surgery: Ibrutinib can interfere with wound healing and increase the risk of bleeding. If you’ve recently had surgery or are planning to have surgery, your doctor may recommend temporarily stopping Ibrutinib.

Drug Interactions with Ibrutinib

Ibrutinib can interact with other medications, potentially increasing the risk of side effects or reducing the effectiveness of either Ibrutinib or the other drugs. Below are some common medications that may interact with Ibrutinib. Always inform your healthcare provider about all the medications you are taking, including over-the-counter drugs and supplements.

1. Antifungal medications: Ketoconazole (Nizoral), Itraconazole (Sporanox), and Voriconazole (Vfend) can increase Ibrutinib levels in your body, raising the risk of side effects.
2. Antibiotics: Clarithromycin (Biaxin) and Erythromycin (Erythrocin) can also increase Ibrutinib levels and should be used with caution.
3. Blood thinners: Warfarin (Coumadin) and other anticoagulants can increase the risk of bleeding when taken with Ibrutinib.
4. Anticonvulsants: Phenytoin (Dilantin) and Carbamazepine (Tegretol) can reduce the effectiveness of Ibrutinib by lowering its levels in the body.
5. St. John’s Wort: This herbal supplement can reduce the effectiveness of Ibrutinib and should be avoided.

Ibrutinib in Pregnancy

Is it safe to take Ibrutinib when pregnant?

Ibrutinib is not considered safe during pregnancy. It can harm an unborn baby, potentially leading to birth defects or miscarriage. If you are pregnant or planning to become pregnant, it is important to avoid taking Ibrutinib. Women of childbearing age should use effective contraception while on Ibrutinib and for at least one month after stopping the medication. If you become pregnant while taking Ibrutinib, contact your healthcare provider immediately for guidance.

Ibrutinib while Breastfeeding

Is it safe to take Ibrutinib while breastfeeding?

It is not recommended to take Ibrutinib while breastfeeding. Although there is no definitive data on whether Ibrutinib passes into breast milk, the potential for serious side effects in a nursing infant suggests that breastfeeding should be avoided. If you are breastfeeding or planning to breastfeed, discuss alternative treatment options with your healthcare provider.

Estimated Cost of Ibrutinib

The cost of Ibrutinib can vary depending on your location and pharmacy. Without insurance, a 30-day supply of Ibrutinib (140 mg tablets) typically ranges between $14,000 and $16,000. However, using a GoodRx coupon may reduce the price to approximately $12,000 to $14,000. Be sure to check with your pharmacy for the most accurate pricing and inquire about any available financial assistance programs that may help lower the cost.

Possible Alternatives to Ibrutinib Treatment

If Ibrutinib is not suitable for you, or if you are exploring alternative treatments, several options are available depending on your specific condition. Always consult your healthcare provider before making any changes to your treatment plan. You can also schedule a telemedicine appointment with one of our providers to discuss your options in more detail.

Chronic Lymphocytic Leukemia (CLL)

Alternative treatments for CLL include Venetoclax (Venclexta), Rituximab (Rituxan), and chemotherapy regimens such as FCR (fludarabine, cyclophosphamide, and rituximab). In addition to medical treatments, lifestyle changes like maintaining a healthy diet and engaging in regular exercise may help improve your overall well-being.

Mantle Cell Lymphoma (MCL)

For MCL, alternatives include Acalabrutinib (Calquence), Bendamustine (Treanda), and Rituximab (Rituxan). In some cases, stem cell transplantation may also be considered as a treatment option.

Waldenström’s Macroglobulinemia (WM)

Potential alternatives for WM include Rituximab (Rituxan) and Bortezomib (Velcade). Some patients may also benefit from plasmapheresis, a procedure that helps reduce blood viscosity.

Small Lymphocytic Lymphoma (SLL)

Common alternatives for SLL include Venetoclax (Venclexta) and Obinutuzumab (Gazyva). Chemotherapy may also be an option, depending on the stage of the disease.

Marginal Zone Lymphoma (MZL)

For MZL, Rituximab (Rituxan) and Bendamustine (Treanda) are potential alternatives. Radiation therapy may also be considered for patients with localized disease.

Acute Lymphoblastic Leukemia (ALL)

Treatment alternatives for ALL include chemotherapy regimens, Tyrosine kinase inhibitors (TKIs) such as Imatinib (Gleevec), and CAR T-cell therapy.

Chronic Graft-Versus-Host Disease (cGVHD)

Common alternatives for managing cGVHD include steroids like Prednisone and immunosuppressants such as Tacrolimus (Prograf). Photopheresis, a procedure that treats blood outside the body, may also be considered.

Multiple Myeloma

For multiple myeloma, alternatives include Lenalidomide (Revlimid), Bortezomib (Velcade), and Daratumumab (Darzalex). Stem cell transplantation may also be an option for some patients.

Follicular Lymphoma

Common alternatives for follicular lymphoma include Rituximab (Rituxan) and Obinutuzumab (Gazyva). Radiation therapy may be considered for patients with early-stage disease.

Diffuse Large B-Cell Lymphoma (DLBCL)

The standard chemotherapy regimen for DLBCL is R-CHOP, which includes Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. For relapsed or refractory cases, CAR T-cell therapy may be an option.

Recent Updates on Ibrutinib Research

Recent studies continue to explore Ibrutinib’s effectiveness in treating various blood cancers. A 2022 study found that combining Ibrutinib with Venetoclax significantly improved outcomes for patients with chronic lymphocytic leukemia (CLL) compared to Ibrutinib alone. Additionally, ongoing clinical trials are investigating the use of Ibrutinib in combination with other targeted therapies for conditions such as mantle cell lymphoma and multiple myeloma.

Researchers are also examining Ibrutinib’s potential in treating autoimmune diseases and inflammatory conditions due to its ability to inhibit certain immune pathways. While these studies are still in the early stages, they offer promising insights into Ibrutinib’s broader applications beyond cancer treatment.

Stay informed about the latest research and discuss new treatment options with your healthcare provider. You can schedule a telemedicine appointment with one of our providers to review the most recent findings and how they may apply to your treatment plan.

James Kingsley

Learn More